Cyclopharm Limited
AASX:CYC0.36
AUD
-0.01
(-2.70%)
ISIN
AU000000CYC5
Return %
Stock
S&P 500
1Y
-48.57
14.20
3Y
-83.78
81.12
5Y
-82.78
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- James M. McBrayer
- Full Time Employees
- 109
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1 The Crescent Kingsgrove NSW Australia 2208
- IPO Date
- Dec 5, 2006
- Website
- cyclopharm.com
- Similar Companies
- Business
- Cyclopharm Limited is an Australian health technology company specializing in the research, development, manufacture, and sale of medical equipment and radiopharmaceuticals primarily used in functional lung ventilation imaging. Its core product is Technegas, a diagnostic imaging technology used globally for the detection of pulmonary embolism and other respiratory conditions such as asthma, COPD, lung cancer, pulmonary hypertension, and long COVID. The company also offers a range of associated consumables and diagnostic kits, alongside a molecular imaging segment producing radiopharmaceuticals for detecting cancer, neurological disorders, and cardiac diseases. Cyclopharm operates through direct sales and third-party distribution partnerships across the Asia Pacific, Europe, Canada, and the United States. Founded in 1990 and headquartered in Sydney, Australia, Cyclopharm has expanded its footprint with regulatory approvals and extensive sales and service networks worldwide. In recent strategic developments, Cyclopharm secured a major three-year contract to deploy Technegas in up to 169 nuclear medicine departments within the Hospital Corporation of America network, marking a significant expansion in the U.S. market. The company also achieved the maximum patent extension of five years for its Technegas technology in the United States, reinforcing its competitive position. Cyclopharm completed a successful $20 million capital raising in 2024 to support U.S. growth initiatives and has launched clinical trials targeting expanded indications of Technegas beyond pulmonary embolism, including chronic respiratory diseases. Operationally, the company renewed regulatory certifications under new MDR and MDSAP standards and reshaped its board to enhance strategic leadership in preparation for growth. Cyclopharm continues to invest in expanding its clinical applications and third-party distribution channels, driving revenue growth with a strong focus on the U.S. and global markets.